Physician profile
Charles E Schultz
NPI 1386693653
$9,227.69
in general payments reported to CMS, 2019-2025
16 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,360 · 2020: $239 · 2021: $166 · 2022: $1,002 · 2023: $878 · 2024: $1,211 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,087.96 | 2019 | |
| Abbvie INC. | $2,048.43 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Amgen INC. | $1,088.00 | 2019-2022 | |
| Lilly USA, LLC | $871.47 | 2019-2023 | Emgality |
| Teva Pharmaceuticals USA, INC. | $557.83 | 2019-2023 | |
| Ucb, INC. | $387.02 | 2023-2025 | Briviact, Nayzilam |
| Lundbeck LLC | $329.35 | 2024-2025 | Vyepti |
| Medtronic, INC. | $288.42 | 2025 | Inceptiv, Synchromedii |
| Alexion Pharmaceuticals, INC. | $149.34 | 2023 | Soliris |
| Axsome Therapeutics, INC. | $124.99 | 2025 | Symbravo |
| Boston Scientific Corporation | $90.03 | 2025 | General - Pain Management |
| Biohaven Pharmaceuticals, INC. | $73.94 | 2021 | |
| Allergan, INC. | $56.67 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $46.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.86 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $13.25 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.